[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Beaumier et al., 2020 - Google Patents

Extracellular vesicular microRNAs as potential biomarker for early detection of doxorubicin‐induced cardiotoxicity

Beaumier et al., 2020

View PDF
Document ID
8929972615089290314
Author
Beaumier A
Robinson S
Robinson N
Lopez K
Meola D
Barber L
Bulmer B
Calvalido J
Rush J
Yeri A
Das S
Yang V
Publication year
Publication venue
Journal of Veterinary Internal Medicine

External Links

Snippet

Background Long‐term use of doxorubicin (DOX) is limited by cumulative dose‐dependent cardiotoxicity. Objectives Identify plasma extracellular vesicle (EV)‐associated microRNAs (miRNAs) as a biomarker for cardiotoxicity in dogs by correlating changes with cardiac …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Similar Documents

Publication Publication Date Title
Beaumier et al. Extracellular vesicular microRNAs as potential biomarker for early detection of doxorubicin‐induced cardiotoxicity
Ghaemmaghami et al. Role of exosomes in malignant glioma: microRNAs and proteins in pathogenesis and diagnosis
van Empel et al. Circulating miRNAs: reflecting or affecting cardiovascular disease?
Levkau et al. Survivin determines cardiac function by controlling total cardiomyocyte number
Zhang et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Tang et al. KLF2 regulates neutrophil activation and thrombosis in cardiac hypertrophy and heart failure progression
Dunlay et al. Tumor necrosis factor-α and mortality in heart failure: a community study
Kai et al. Expression of proto-oncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy
Liu et al. Angiotensin II stimulation in vitro induces hypertrophy of normal and postinfarcted ventricular myocytes
Lerchenmüller et al. CITED4 protects against adverse remodeling in response to physiological and pathological stress
Shah et al. MicroRNAs associated with reverse left ventricular remodeling in humans identify pathways of heart failure progression
Hulanicka et al. Plasma miRNAs as potential biomarkers of chronic degenerative valvular disease in Dachshunds
Gao et al. Identification of rare variants in ATP8B4 as a risk factor for systemic sclerosis by whole‐exome sequencing
Hill et al. Intravenous glial growth factor 2 (GGF2) isoform of neuregulin-1β improves left ventricular function, gene and protein expression in rats after myocardial infarction
JP6923215B2 (en) Anti-HTLV-1 agent, HTLV-1-related myelopathy (HAM / TSP) therapeutic agent
Su et al. MiRNA expression profile of the myocardial tissue of pigs with coronary microembolization
Lee et al. Cancer metabolism as a mechanism of treatment resistance and potential therapeutic target in hepatocellular carcinoma
Zhou et al. Circulating exosomal microRNAs as emerging non‐invasive clinical biomarkers in heart failure: mega bio‐roles of a nano bio‐particle
Kitow et al. Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic cardiomyopathy
Zhao et al. Dysregulated miR1254 and miR579 for cardiotoxicity in patients treated with bevacizumab in colorectal cancer
Ni et al. Trophoblast stem-cell-derived exosomes improve doxorubicin-induced dilated cardiomyopathy by modulating the let-7i/YAP pathway
Kouzu et al. ZFP36L2 suppresses mTORc1 through a P53-dependent pathway to prevent peripartum cardiomyopathy in mice
Stamm et al. Doxorubicin induces wide-spread transcriptional changes in the myocardium of hearts distinguishing between mice with preserved and impaired cardiac function
Kennel et al. Longitudinal profiling of circulating miRNA during cardiac allograft rejection: a proof‐of‐concept study
Han et al. Metabolic labeling of cardiomyocyte‐derived small extracellular‐vesicle (sEV) miRNAs identifies miR‐208a in cardiac regulation of lung gene expression